News
News Center
2022-01-19
This special support program includes two key components: a major public service platform for the biopharmaceutical industry and a core technology research initiative, as well as a city-level public technical service platform upgrade program. Under the program, up to 300 million yuan in funding is available for tackling critical core technologies.
+
2022-01-18
Provincial Political Consultative Conference members Wu Jinming, Kong Heping, Chen Hongzhong, and Zheng Ansheng jointly proposed that Hunan should follow the practices of cities like Tianjin and Shenzhen, granting clinical institutions within the free trade zone permission to carry out clinical applications of stem-cell therapies as well as charge cost-based fees.
+
2022-01-11
Jiuzhitang Maker wins two major awards at the "2021 Brand Powerhouse Economic Forum (5th Edition)"
On January 7, 2022, the "2021 Brand Power Economic Forum & (5th) Innovation Achievement Promotion Event" was held in Hainan. Jiuzhitang Maker was invited to attend and proudly won two prestigious awards: "2021 Innovation China – Top 100 Innovative Enterprises" and "2021 Brand Power – Top 10 Innovative Enterprises in the Biopharmaceutical Industry."
+
2022-01-10
On January 6, 2022, to implement the "Drug Administration Law of the People's Republic of China," the National Medical Products Administration (NMPA) publicly released the draft "Appendix to the Pharmaceutical Production Quality Management Regulations—Cell Therapy Products" for public comment through its Comprehensive Department, inviting input from society.
+
2022-01-05
TED Talk: The Future of Medicine—Healing with Cells, Not Pills!
The future of medicine will transform the way we treat diseases. Soon, we’ll be using cell-based therapies instead of pills.
+
2021-12-20
On December 18, 2021, the 5th session of the 4th Council Meeting of the China Association of Traditional Chinese Medicine was held in Beijing. During the meeting, the 2021 Annual Information on the TCM Industry was officially unveiled via live-streaming online. Notably, Jiuzhitang Shuxuetong Injection, Liuwei Dihuang Wan, and Tianma Gouteng Granules proudly made it onto the 2021 List of Clinically Valuable Brands of Traditional Chinese Medicines!
+
2021-12-20
Jiuzhitang ranked 26th among the Top 100 Traditional Chinese Medicine Brands in 2021!
On December 18, 2021, the 5th session of the 4th Council Meeting of the China Association of Traditional Chinese Medicine was held in Beijing. During the meeting, Liu Zhanglin, Vice President of the China Association of Traditional Chinese Medicine, officially unveiled the 2021 Top 100 List of Traditional Chinese Patent Medicines via online livestream. Notably, Jiuzhitang Co., Ltd. was honorably recognized, ranking 26th on the list!
+
2021-12-07
On December 3, the General Office of the People's Government of Yuexiu District, Guangzhou, officially issued the "Notice on the '14th Five-Year' Plan for Science and Technology Innovation and Strategic Emerging Industry Development in Yuexiu District, Guangzhou."
+
2021-12-06
Support innovative R&D initiatives! Companies can receive up to 100 million in funding annually.
Supporting innovative drug research and development. For new drugs that initiate clinical trials and are subsequently translated for implementation in Daxing District, phased support will be provided based on their R&D progress.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy